Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline
Abstract
Increased presynaptic dysfunction measured by cerebrospinal fluid (CSF) growth‐associated protein‐43 (GAP43) may be observed in Alzheimer's disease (AD), but how CSF GAP43 increases relate to AD‐core pathologies, neurodegeneration, and cognitive decline in AD requires further investigation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 15, 2022
- Source ID
- 10.1002/ana.26492
Entities
People
- Anqi Li
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Guoyu Lan
- Shaohua Ma
- Tengfei Guo
- Yue Cai
- Zhen Liu
Organizations
- Bristol Myers Squibb (Canada)
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Hoffmann-La Roche
- Johnson & Johnson
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- National Natural Science Foundation of China
- Northern California Institute for Research and Education
- Peking University
- Takeda (United States)
- Tsinghua University
- United States Department of Defense
- University of California, San Diego
- University of Southern California